Close Menu

NEW YORK — Prescient Metabiomics said on Tuesday that it has partnered with the Harvard TH Chan School of Public Health to investigate microbiome biomarkers in colon cancer.

Under the terms of the deal, Prescient Metabiomics and collaborators at the Harvard Chan Microbiome in Public Health Center will study the use of microbial biomarkers to identify precancerous adenomas and carcinomas in the colon. The effort will initially use bioinformatic approaches to analyze colorectal cancer cases across different populations, focusing on prevalent gut microbial biomarkers for the disease.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Mar
11
Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
17
Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar
23
Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
24
Sponsored by
Mission Bio

This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.